// App-Quantinova.ai

P4-01-08 : Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer Results of the German SUCCESS trials

Researchers

Presenter

  • Jaeger BAS

Principal Investigators

  • Andergassen U

  • Neugebauer JK

  • Schneeweiss A

  • Beckmann MW

  • Pantel K

  • Friese K

  • Fasching PA

  • Friedl TWP

  • Janni W

  • Rack BKAlunni-Fabbroni MMelcher CA

  • Hagenbeck C

  • Albrecht S

  • Lorenz R

  • Decker T

  • Heinrich G

  • Fehm T

Medical Centers

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Praxis Dr. Heinrich, Fuerstenwalde, GermanyInstitute for Tumor Biology, Center of Experimental Medicine, University Medical Center, Hamburg, GermanyGemeinschaftspraxis Dr. Lorenz / Hecker /Wesche, Braunschweig, Germany

  • Studienzentrum Onkologie Ravensburg, Ravensburg, Germany

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMNUniversity Hospital, Erlangen, Germany

  • Klinikum Augsburg, Ludwig-Maximilians-University, Munich, Germany

  • University of Ulm, Ulm, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Zoledronic acid

  • Gemcitabine

  • Trastuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved